Trial reportDigestive diseases and sciences2016
A Randomized Controlled Comparison of Esophageal Clearance Times of Oral Budesonide Preparations.
Trial report in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Clearance of corticosteroids in pediatric patients with active eosinophilic esophagitis: Faster than expected.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Orally Dispersible Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Paradigm Shift in the Management of Esophageal Inflammation.Pharmaceutics · 2025Review
- Modification of the Biorelevant Release Testing of Esophageal Applied Mucoadhesive Films and Development of Formulation Strategies to Increase the Mucosal Contact Time.Pharmaceutics · 2024Article
- Geographical Origin Authentication-A Mandatory Step in the Efficient Involvement of Honey in Medical Treatment.Foods (Basel, Switzerland) · 2024Review
- Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors.Drug delivery · 2023Review
- Development of Test Programs for the Biorelevant Characterization of Esophageal-Applied Dosage Forms.Polymers · 2023Article
- Medical treatment of eosinophilic esophagitis.The Cochrane database of systematic reviews · 2023Review
- A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature.Journal of clinical medicine · 2022Article
- Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities.Journal of clinical medicine · 2022Review
- Transcranial direct current stimulation over the posterior parietal cortex improves visuomotor performance and proprioception in the lower extremities.Frontiers in human neuroscience · 2022Article
- Red Between the Lines: Evolution of Eosinophilic Esophagitis as a Distinct Clinicopathologic Syndrome.Digestive diseases and sciences · 2020Review
- Reply to "Comment on Casiraghi et al. 'Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis' 2020,Pharmaceutics · 2020Article
- Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis.Pharmaceutics · 2020Article
- Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use.Clinical and translational gastroenterology · 2018Review
- White Paper AGA: Drug Development for Eosinophilic Esophagitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017Review
- Management of refractory eosinophilic oesophagitis.Nature reviews. Gastroenterology & hepatology · 2017Review
- Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives.Frontiers in medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTopical steroids prepared as oral viscous slurries have become common in the treatment of eosinophilic esophagitis. Esophageal mucosal contact time correlates with clinical and histologic improvement.
aimTo compare the mucosal contact time of alternative oral viscous budesonide (OVB) slurries with the conventional sucralose OVB.
methodsA blinded randomized crossover trial investigating esophageal clearance of three OVB slurry preparations was done on healthy adults. Honey and xanthan gum OVB slurries were compared with standard sucralose OVB in 24 randomly assigned subjects. Each subject ingested the sucralose OVB and either the honey or xanthan gum OVB slurries. The esophageal clearance of each slurry was evaluated as an area under the curve (AUC) using 1 millicurie of technetium-99m-sulfur colloid (Tc99) co-administered in each OVB preparation using nuclear scintigraphy. A standardized taste survey was also administered.
resultsXanthan gum had greater mucosal contact time compared to sucralose as measured by a higher AUC at 3 min (P = 0.002), while honey showed no significant difference in esophageal clearance relative to sucralose. Taste scores were significantly higher in the honey group, while scores for xanthan gum were no different from standard sucralose.
conclusionOVB slurries utilizing xanthan gum may be a superior alternative to a sucralose-based slurry due to its increased mucosal contact time and similar taste tolerance. Honey may be a suitable alternative as well, due to its similar contact time and favorable taste.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.